Kolexia
Tarte Karin
Pharmacien
Hôpital Pontchaillou
Rennes, France
267 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome folliculaire Lymphome B Lymphome B diffus à grandes cellules Sclérose Sepsie Lymphome malin non hodgkinien Maladie de Hodgkin Sclérose en plaques

Industries

BMS
2 collaboration(s)
Dernière en 2021
Amgen
2 collaboration(s)
Dernière en 2022
Gilead
1 collaboration(s)
Dernière en 2020
Roche
1 collaboration(s)
Dernière en 2021

Dernières activités

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
Essai Clinique (Roche)   13 mars 2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee.
EClinicalMedicine   10 février 2024
NGFR regulates stromal cell activation in germinal centers.
Cell reports   01 février 2024
Redtalks s2e1 - A macro view of the tumoral microenvironment
Youtube @ Institut CARNOT CALYM   18 janvier 2024
Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
Blood   14 décembre 2023
KDM6B drives epigenetic reprogramming associated with lymphoid stromal cell early commitment and immune properties.
Science advances   29 novembre 2023
Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.
Frontiers in immunology   02 novembre 2023
Single-Cell Longitudinal Characterization of FL Heterogeneity and Residual Disease in the Bone Marrow from Low-Tumor Burden FL Enrolled in the Flirt Clinical Trial
65th ASH Annual Meeting Abstracts   02 novembre 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Nature medicine   31 octobre 2023